A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1

Journal of Immunological Methods

Volumn 279, Issue 1-2, 2003, Pages 183-192

  Arlen, Philip M ^a   Gulley, James L ^a   Palena, Claudia ^a   Marshall, John ^b   Schlom, Jeffrey ^a   Tsang, Kwong Yok ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antigen presenting cells; Costimulation; ELISPOT; Immunoassay; Pox vectors; T cells

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VECTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION; FLOW CYTOMETRY; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WILD TYPE;

DNA VIRUSES; FOWLPOX VIRUS; TRIXIS;

EID: 0142092628     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00185-6     Document Type: Article

References (31)

1. Alters S.E., Gadea J.R., Sorich M., O'Donoghue G., Talib S., Philip R. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J. Immunother. 21:1998;17.
2. Arlen P., Tsang K.Y., Marshall J.L., Chen A., Steinberg S.M., Poole D., Horan Hand P., Schlom J., Hamilton J.M. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother. 49:2000;517.
3. Chakraborty N.G., Sporn J.R., Tortora A.F., Kurtzman S.H., Yamase H., Ergin M.T., Mukherji B. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 47:1998;58.
4. Eder J.P., Kantoff P.W., Roper K., Xu G., Bubley G.J., Boyden J., Oh W.K., Horzempa M.L., Arlen P., Tsang K.Y., Panicali D., Schlom J., Kufe D.W. A Phase I trial of a recombinant vaccinia virus expressing prostate specific antigen in advanced prostate cancer. Clin. Cancer Res. 6:2000;1632.
5. Guadagni F., Witt P.L., Robbins P.F., Schlom J., Greiner J.W. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-γ Cancer Res. 50:1990;6248.
6. Gulley J., Chen A., Dahut W., Arlen P., Bastian A., Steinberg S., Tsang K., Panicali D., Poole D., Schlom J., Hamilton J.M. A Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 53:2002;109.
7. Hogan K.T., Shimojo N., Walk S.F., Engelhard V.H., Maloy W.L., Coligan J.E., Biddison W.E. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J. Exp. Med. 168:1988;725.
8. Huet S., Groux H., Caillou B., Valentin H., Prieur A.M., Bernard A. CD44 contributes to T cell activation. J. Immunol. 143:1989;798.
9. Jennes W., Kestens L., Nixon D.F., Shacklett B.L. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15 - the Amplispot assay. J. Immunol. Methods. 270:2002;99.
10. Judge T.A., Tang A., Turka L.A. Immunosuppression through blockade of CD28: B7-mediated costimulatory signals. Immunol. Res. 15:1996;38.
11. Kawaguchi M., Eckels D.D. Differential activation through the TCR-CD3 complex affects the requirement for costimulation of human T cells. Hum. Immunol. 43:1995;136.
12. Larsson M., Jin X., Ramratnam B., Ogg G.S., Engelmayer J., Demoitie M.A., McMichael A.J., Cox W.I., Steinman R.M., Nixon D., Bhardwaj N. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS. 13:1999;767.
13. Liu Y., Linsley P.S. Costimulation of T-cell growth. Curr. Opin. Immunol. 4:1992;265.
14. Marshall J.L., Hoyer R.L., Toomey M.A., Faraguna K., Richmond E., Pedicano J.E., Gehan E., Peck R., Arlen P., Tsang K.Y., Schlom J. Phase I study in cancer patients of a diversified prime and boost immunization protocol using recombinant nonreplicating avian pox virus to elicit an anti-carcinoembryonic antigen immune response. J. Clin. Oncol. 18:2000;3964.
15. Meidenbauer N., Harris D.T., Spitler L.E., Whiteside T.L. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 43:2000;88.
16. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:1989;445.
17. Pellegrini P., Berghella A.M., Del Beato T., Cicia S., Adorno D., Casciani C.U. Disregulation of TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42:1996;1.
18. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.M., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wonderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321.
19. Scheibenbogen C., Lee K.H., Mayer S., Stevanovic S., Moebius U., Herr W., Rammensee H.G., Keilholz U. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:1997;221.
20. Schmitz M., Rohayem J., Paul R., Weigle B., Stein A., Rieber E.P. Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells. J. Clin. Lab. Anal. 16:2002;30.
21. Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138:1987;1657.
22. Tai X.G., Yashiro Y., Abe R., Toyooka K., Wood C.R., Morris J., Long A., Ono S., Kobayashi M., Hamaoka T.et al. A role for CD9 molecules in T cell activation. J. Exp. Med. 184:1996;753.
23. Tai X.G., Toyooka K., Yashiro Y., Abe R., Park C.S., Hamaoka T., Kobayashi M., Neben S., Fujiwara H. CD9-mediated costimulation of TCR-triggered naive T cells leads to activation followed by apoptosis. J. Immunol. 159:1997;3799.
24. Tsang K.Y., Zhu M., Even J., Gulley J., Arlen P., Schlom J. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific Cytolytic T cells. Cancer Res. 61:2001;7568.
25. Von Mehren M., Arlen P., Tsang K.Y., Rogatko A., Meropol N., Cooper H.S., Davey M., McLaughlin S., Schlom J., Weiner L.M. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6:2000;2219.
26. + T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J. Immunol. 164:2000;1216.
27. Watts T.H., DeBenedette M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:1999;286.
28. Yashiro Y., Tai X.G., Toyo-oka K., Park C.S., Abe R., Hamaoka T., Kobayashi M., Neben S., Fujiwara H. A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co-stimulatory molecules. Eur. J. Immunol. 28:1998;926.
29. Zajac P., Schutz A., Oertli D., Noppen C., Schaefer C., Heberer M., Spagnoli G.C., Marti W.R. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res. 58:1998;4567.
30. Zaremba S., Barzaga E., Zhu M.Z., Soares N., Tsang K.Y., Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57:1997;4570.
31. Zhou X.Y., Yashiro-Ohtani Y., Nakahira M., Park W.R., Abe R., Hamaoka T., Naramura M., Gu H., Fujiwara H. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J. Immunol. 168:2002;3847.